Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Zacks.com on MSN1d
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback